In recent years, the pharmaceutical industry is setting off a wave of extensive cooperation
.
Among them, the "marriage" of cooperation between innovative pharmaceutical companies and multinational pharmaceutical companies, and between local pharmaceutical companies and innovative pharmaceutical companies, is constantly emerging, and the amount of cooperation involved is huge
.
At the end of this year, a large number of pharmaceutical companies have announced cooperation news
.
Among them, it is worth noting that the cooperation of these pharmaceutical companies involves the development of
new drugs.
GenFleet partners with Merck of Germany
On December 19, GenFleet announced that it has entered into a European multi-center clinical research and drug supply collaboration agreement with Merck KGaA to conduct a Phase 1b/2 clinical study of GenFleet's combination therapy with KRAS G12C inhibitor GFH925 and Merck's anti-EGFR antibody cetuximab injection to evaluate the effectiveness
of this combination therapy in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC).
GenFleet's collaboration will be a new starting point
for its multi-center clinical development in Europe.
As the company continues to achieve milestones in its internationalization process, it is believed that the cooperation with Merck will further highlight GenFleet's forward-looking advantages and differentiated development results
.
Sosei Heptares and Eli Lilly enter into a drug discovery collaboration
On December 19, biopharmaceutical company Sosei Heptares and Eli Lilly recently announced a drug discovery collaboration to jointly discover, develop and commercialize small molecule drugs targeting innovative G protein-coupled receptor (GPCR) targets for the treatment of diabetes and metabolic diseases
.
Under the protocol, Sosei Heptares will discover target-specific small molecule lead compounds based on multiple GPCR targets specified by Eli Lilly for further development and commercialization
.
Sosei Heptares will receive an upfront payment of $37 million and may receive up to $694 million in development and commercialization milestone payments
.
Doyle Biologics and Merck reached a clinical trial collaboration
On December 16, Zhejiang Daoer Biotechnology Co.
, Ltd.
announced that it has reached a clinical trial cooperation agreement with Merck to explore the clinical trial
of Doyle Biologics anti-Claudin18.
2 antibody DR30303 and Merck's PD-1 inhibitor KEYTRUDA® (pembrolizumab) in the treatment of gastric cancer or gastroesophageal junction cancer.
According to the agreement, Doyle Biologics will conduct clinical trials based on mutually agreed and finalized clinical protocols to evaluate the safety and efficacy
of DR30303 in combination with KEYTRUDA® in patients with Claudin18.
2-positive, locally advanced unresectable or metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJ).
epilogue
From the above point of view, cooperation is still the main path
for win-win research and development of new drugs.
Analysts believe that in the context of pharmaceutical innovation becoming the general trend of industry development and market competition is intensifying, in order to strengthen and expand R&D pipelines and accelerate the commercialization of products, strong alliances between pharmaceutical companies will become more and more common
in the industry.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
